Quarterly ResultMay 7, 2026, 04:31 PM
Tectonic Therapeutic Q1 Net Loss Widens to $25.2M
AI Summary
Tectonic Therapeutic, Inc. reported a significant increase in its net loss for the first quarter of 2026, reaching $25.2 million, up from $15.9 million in the prior year. This was primarily driven by a substantial rise in research and development expenses. The company also utilized its at-the-market offering program, raising $1.3 million in net proceeds during the quarter.
Key Highlights
- Net loss for Q1 2026 was $25.2 million, up from $15.9 million in Q1 2025.
- Research and development expenses increased to $20.9 million from $13.0 million.
- General and administrative expenses rose to $6.4 million from $5.3 million.
- Net loss per share was $(1.34) for Q1 2026, compared to $(0.93) in Q1 2025.
- Cash and cash equivalents stood at $236.9 million as of March 31, 2026.
- Net cash used in operating activities was $18.4 million for Q1 2026.
- Raised $1.3 million net proceeds from at-the-market offering.
Price Impact
More from TECX